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Abstract
Background: Spinal cord injury is a major cause of long-term disability and has no current clinically accepted treatment.
Leptin, an adipocyte-derived hormone, is best known as a regulator of food intake and energy expenditure. Interestingly,
several studies have demonstrated that leptin has significant effects on proliferation and cell survival in different
neuropathologies. Here, we sought to evaluate the role of leptin after spinal cord injury.
Findings: Based on its proposed neuroprotective role, we have evaluated the effects of a single, acute intraparenchymal
injection of leptin in a clinically relevant animal model of spinal cord injury. As determined by quantitative Real Time-PCR,
endogenous leptin and the long isoform of the leptin receptor genes show time-dependent variations in their expression in
the healthy and injured adult spinal cord. Immunohistochemical analysis of post-injury tissue showed the long isoform of
the leptin receptor expression in oligodendrocytes and, to a lesser extent, in astrocytes, microglia/macrophages and
neurons. Moreover, leptin administered after spinal cord injury increased the expression of neuroprotective genes, reduced
caspase-3 activity and decreased the expression of pro-inflammatory molecules. In addition, histological analysis performed
at the completion of the study showed that leptin treatment reduced microglial reactivity and increased caudal myelin
preservation, but it did not modulate astroglial reactivity. Consequently, leptin improved the recovery of sensory and
locomotor functioning.
Conclusions: Our data suggest that leptin has a prominent neuroprotective and anti-inflammatory role in spinal cord
damage and highlights leptin as a promising therapeutic agent.
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Introduction
Leptin, the product of the obese (ob) gene [1], is a polypeptide
hormone primarily secreted by adipocytes that exerts its main
biological functions in the brain [2,3]. This 16-kDa non-
glycosylated protein is first released into the blood and then
transported into the brain via the blood-brain barrier to regulate
food intake and energy balance [4]. Leptin acts by binding to its
receptors that are structurally related to the cytokine receptor class
I family. Alternative splicing of the diabetes (db) gene generates
distinct isoforms of the leptin receptor, including long (ObRb) and
short isoforms (ObRa and ObRc-f) that differ in the length of their
intracellular cytoplasmic domains, a region that contains specific
motifs involved in leptin signaling [1,5]. The long isoform of the
leptin receptor (ObRb) is thought to transmit the majority of
leptin’s biological signals. In the brain, the binding of leptin to the
ObRb receptor activates janus-tyrosine kinase 2 (JAK2), which in
turn phosphorylates the insulin receptor substrate-1 and -2 (IRS
1/2) that results in the activation of the phosphatidylinositol 3-
kinase (PI3K)-akt pathway [6,7]. JAK2 activation also leads to the
phosphorylation of two tyrosine residues in the cytoplasmic tail of
the ObRb receptor [8], producing the activation of the mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) [9,10] and the signal transducer and activator of
transcription 3 (STAT3) signaling pathways [8].
Indeed, several studies have demonstrated significant effects of
leptin on reproduction [11], thermogenesis [12], synaptic plasticity
[13] and neuroprotection [14–17]. In this regard, leptin promotes
cell survival and proliferation in the nervous tissue via signaling
pathways downstream of leptin receptors [14–17]. Leptin has been
shown to exert neuroprotective effects in ischemia [16], Parkin-
son’s and Alzheimer’s diseases [18–24] and epilepsy [25], and
systemic administration of leptin decreases infarct volume after
focal cerebral ischemia in mice [16]. Taken together, these
findings highlight the therapeutic potential of leptin as a treatment
for a variety of central nervous system (CNS) disorders.
Spinal cord injury (SCI) is a major cause of long-term functional
disability for which no clinically satisfactory treatment is yet
available [26]. The loss of sensory-motor function after SCI,
results from primary mechanical damage and the ensuing
secondary neural cell death [27,28]. Despite significant progress,
the precise mechanisms underlying this secondary cell death
remain unclear. In this regard, it is plausible that leptin may
influence cell survival in the spinal cord after injury. Accordingly,
the aim of this study was to determine the effects of an acute,
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with previous findings, we found that leptin administration
enhances the expression of neuroprotective genes, reduces
inflammation and significantly improves sensory and motor
function after SCI.
Results
Leptin and ObRb are up-regulated after SCI
We confirmed that endogenous leptin and ObRb genes were
expressed in non-lesioned spinal cord samples (NL). Strikingly, we
detected marked differences in the expression of both leptin and
OBRb mRNA following SCI when compared with the NL
samples. More specifically, there was a down-regulation of leptin
(Figure 1A) and an up-regulation of ObRb (Figure 1B) mRNA
expression 6 hours (h) post-SCI, followed by a significant increase
in the expression of both mRNA transcripts from 24 h to 7 days (d)
post-SCI. However, at 14 d post-SCI, the ObRb mRNA
expression returned to the basal level observed in the NL spinal
cords (Figure 1B).
ObRb is expressed in neural cells
Dual immunohistochemistry (IHC) analyses were performed in
spinal cord sections from uninjured and injured vehicle/leptin-
treated rats at 24 h post-SCI. In uninjured spinal cord sections
ObRb was found primarily in neurons and oligodendrocytes and,
to a lesser extent, in astrocytes and microglia/macrophages
(Figure 2A–D). Otherwise, at 24 h post-SCI ObRb was found
primarily in oligodendrocytes and, to a lesser extent, in astrocytes
and microglia/macrophages in both rostral and caudal unaffected
areas (Figure 2F–H) and in the lesion epicentre (Figure 2I–K).
Finally, neuronal ObRb receptor expression was detected in both
rostral and caudal unaffected areas (Figure 2E). Notably, the
cellular ObRb expression pattern was identical between treatment
groups (data not shown).
Leptin increases the expression of neuroprotective genes
after SCI
Western blot analysis of neuroprotective gene expression
showed that leptin-treated animals displayed a significant increase
in the protein levels of B-cell lymphoma/leukemia 2 (Bcl-2) at 7
and 28 d post-SCI and in the protein levels of B-cell lymphoma-
extra-large (Bcl-xL) and active phosphorylated CREB (p-CREB) at
all analysed time points (Figure 3A). Quantitative Real Time-PCR
(RT-qPCR) analysis revealed a significant up-regulation of
catalase and glutathione peroxidase (GPx) mRNA expression in
leptin-treated animals (Figure 3B and 3C). In addition, there was a
significant decrease in caspase-3 activity in leptin-treated rats at
24 h and 7 d after injury when compared with control rats
(Figure 3D).
Leptin ameliorates the expression of inflammatory genes
We evaluated the effect of leptin treatment on the expression of
a wide range of pivotal inflammatory-related molecules, such as
peroxisomal proliferator activated receptors (PPARs), pro-inflam-
matory transcription factors, cytokines and enzymes using western
blot or RT-qPCR techniques. Our results showed a significant
increase in the expression of PPARa mRNA (Figure 4A) 24 h
post-SCI but no differences in PPARc mRNA expression
(Figure 4B). At this time point, we also observed a significant
decrease in the expression of interferon regulatory factor-1 (IRF-1)
and nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kb) in leptin-treated animals when compared with the controls
(Figure 4C and 4D) however, no differences in inducible nitric
oxide synthase (iNOS), interleukin (IL)-1b and IL-6 mRNA
expression were detected (Figure 4E). At 7 and 28 d post-SCI,
there was a significant decrease in iNOS and IL-1b mRNA
expression coupled with an increase in IL-6 expression in leptin-
treated animals when compared with control animals (Figure 4E).
No changes in tumor necrosis factor-alpha (TNF-a) mRNA
expression were observed at any of the time points analysed
(Figure 4E). Lastly, these changes at the mRNA level were
concomitant with a decrease in cyclooxigenase-2 (Cox-2) and
active phosphorylated STAT3 (p-STAT3) protein levels
(Figure 4F).
Leptin enhances functional motor recovery and prevents
the development of neuropathic pain after SCI
Prior to injury, all rats showed a maximum Basso, Beattie,
Bresnahan (BBB) [29] score of 21, indicating normal motor
function. At 1 d post-SCI the BBB score was less than 3 in all of
the vehicle-treated rats, indicating an almost complete loss of
motor function. Strikingly, all rats from the leptin-treated group
attained BBB scores greater than 3, indicating a significant
Figure 1. Leptin and ObRb are up-regulated after SCI. The
expression of leptin (A) and ObRb (B) was quantified by RT-qPCR using
specific primers (Table 1). The mRNA expression of ObRb was
significantly increased 6 h post-SCI, while the mRNA expression of
leptin was decreased. At 24 h, 3 d and 7 d post-SCI, the expression of
both mRNAs was significantly increased. At 14 d post-SCI, leptin mRNA
expression remained up-regulated, while ObRb mRNA expression had
returned to the basal levels observed in the non-lesioned group (NL).
Differences were calculated by setting the expression values of the NL
samples at 1 and normalising against ribosomal 18S rRNA. The
differences are shown as the mean 6 SEM; *p,0.05 versus NL.
doi:10.1371/journal.pone.0035594.g001
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(Figure 5A). The initial improvement in motor function was
sustained, with significantly higher scores in the leptin-treated
group when compared with controls, except at 14 and 21 d after
injury. These changes could be due to the intrinsic limitations of
the BBB scale, as evidenced by the significantly higher total BBB
sub-score of the leptin-treated group when compared with the
vehicle group at 7, 21 and 28 d post-SCI (Figure 5B). In fact, when
the total sub-scores were examined individually, only the leptin-
treated animals could step 7 d after injury, with the coordination
sub-scores reaching significance at 21 and 28 d post-SCI. Indeed,
at these time points both toe clearance and paw positions were
improved by leptin treatment (Figure S1A–D). Finally, leptin-
treated rats were able to lift their tail during locomotion earlier
than the vehicle-treated rats, suggesting better overall stability
(data not shown). Thus, leptin-treated rats stepped earlier and
displayed a more normal stepping pattern when compared with
the vehicle-treated animals. Accordingly, the CatWalk gait
assessment at 28 d post-SCI revealed a significant functional
improvement in the leptin-treated group as shown by a decrease in
the base of support (BOS), a reduction in the distance between
consecutive fore and hind paw placement and a more parallel paw
position relative to the advancing axis (Figure 6A–G). Indeed,
electrophysiological recordings of hind limb motor evoked
potentials (MEPs) revealed an improved capacity for transmission
of neural motor impulses through the injury site in leptin-treated
animals when compared with the vehicle-treated animals
(Figure 7A and 7B). We also assessed the effects of leptin
administration on hyperalgesia and allodynia in a random subset
of animals at the completion of the study. Interestingly, leptin
treatment prevented the development of the thermal hyperalgesia
(Figure 7C) and allodynia (Figure 7D) that was observed in animals
treated with the vehicle.
Leptin decreases chronic microglia/macrophage
activation and caudal white matter loss after spinal cord
damage
Analysis of white-matter preservation at 28 d post-SCI revealed
a higher percentage of myelin preservation in caudal levels
adjacent to the lesion epicentre in leptin-treated animals (Figure 8).
We also evaluated astroglial and microglial reactivity (Figure 9) at
the same time point. Notably, leptin treatment induced a
significant decrease in the overall total volume occupied by
Iba1
+ reactive microglia/macrophages (Figure 9A) and at multiple
rostro-caudal levels of the injury site (Figure 9B). However, no
differences were detected between vehicle and leptin-treated
groups either in total volume (Figure 9C) or in the area occupied
Figure 2. Immunohistochemical analysis of ObRb expression after SCI. Dual immunohistochemistry was performed in uninjured spinal cord
sections, and 24 h post-SCI on spinal cord sections from vehicle-treated and leptin-treated animals. ObRb immunolabelling was observed in
uninjured spinal cord sections (A to D) and in both rostral and caudal unaffected areas (E to H) and at the lesion epicentre (I to K). Cells expressing
ObRb were identified as NeuN
+ neurons (A and E), APC
+ oligodendrocytes (B, F and I), GFAP
+ astrocytes (C, G and J) and OX-42
+ microglia/
macrophages (D, H and K). Scale Bars=20 mm.
doi:10.1371/journal.pone.0035594.g002
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xL and p-CREB proteins when compared with vehicle-treated controls. Bcl-2 protein levels were increased significantly beginning at 7 d post-SCI and
remained elevated until 28 d post-SCI. Bcl-xL and p-CREB protein levels were increased significantly beginning at 24 h post-SCI and remained
elevated until 28 d post-SCI when compared with vehicle-treated controls. (B and C) An increase in antioxidant enzyme mRNA expression was
observed in leptin-treated animals when compared with vehicle treated controls. In leptin-treated animals, catalase gene expression (B) was
significantly increased after 24 h and remained elevated until 28 d post-SCI. GPx gene expression (C) was significantly increased after 7 d and
remained elevated until 28 d after injury. (D) In the early stages after injury (24 h and 7 d post-SCI), leptin treatment decreased caspase-3 activity,
while at later stages (28 d post-SCI) no differences were detected when compared with vehicle-treated controls. The white lines in the western blot
analysis (A) represent the lanes that were run on the same gel but were non-contiguous. The data in (A) are presented as a percentage of the
corresponding value in the vehicle-treated control group 24 h post-SCI. The values in A–D represent the mean 6 SEM; *p,0.05 versus the vehicle
control group.
doi:10.1371/journal.pone.0035594.g003
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(Figure 9D).
RT-qPCR analysis at 28 d post-SCI revealed a significant up-
regulation of PPARa and PPARb/d mRNA expression in
response to leptin treatment (Figure 10A and 10B), while no
differences were detected in PPARc mRNA expression
(Figure 10C). Moreover, we observed a significant down-
regulation of NF-kb mRNA (Figure 10D) and an increase in
decorin mRNA expression (Figure 10E) in leptin-treated animals.
Discussion
Our results demonstrate that endogenous leptin and ObRb
receptor is expressed in NL spinal cords and that there is a time-
dependent up-regulation of these genes following a moderate
contusive SCI. At 6 h post-SCI, we observed a significant decrease
in leptin mRNA paralleled by an increase in ObRb mRNA
expression. Thus, we decided to administer a single injection of
recombinant leptin 5 min after SCI. This resulted in an activation
of intracellular signaling pathways that promoted the expression of
neuroprotective genes and antioxidant enzymes, as well as,
prevented the expression of pro-inflammatory transcription
factors, cytokines and enzymes. We also demonstrated a significant
improvement in sensory and motor functional outcomes with
leptin treatment after SCI.
In spinal cord neuropathology, sensory-motor functional loss
results from the primary mechanical impact and the multifaceted
secondary degenerative response that is promoted by a combina-
tion of deleterious processes, including inflammation, excitotoxic-
ity and the generation of a glial scar that strongly inhibits axon
growth [30]. The secondary degenerative response, due to
apoptosis and an early inflammatory response that occurs between
8 h and 1 week post-SCI, is characterised by demyelination,
axonal injury and the destruction of nervous tissue that survived
the initial impact [31]. Based on the recently reported anti-
apoptotic activity of leptin in different cell types [14,15,17], we
evaluated ObRb immunoreactivity after SCI. We observed ObRb
immunoreactivity in oligodendrocytes and, to a lesser extent, in
astrocytes, microglia/macrophages and neurons. Moreover, we
quantified the mRNA expression of antioxidant enzymes that
mediate the metabolism of free radicals [28] and the level of anti-
apoptotic proteins because many survival genes are down-
regulated in the acute phase of SCI and the onset of secondary
cell death [31]. Interestingly, an IP injection of leptin induced the
mRNA expression of the antioxidant enzymes catalase and GPx
[28], the anti-apoptotic proteins Bcl-2 and Bcl-xL and increased p-
CREB protein levels, a potent pro-survival transcription factor
downstream of the ERK 1/2 target gene [15]. In addition, leptin
treatment decreased cell death, as evidenced by a decrease in
caspase-3 activity, a significant preservation of the white matter in
the caudal levels adjacent to the lesion epicentre and an increase in
PPARb/d mRNA expression, a transcription factor expressed by
oligodendrocytes and glial precursors known to promote neuro-
protection [32] and myelination [33]. Therefore, we cannot rule
out that the survival effects of leptin could be largely due to specific
activation of the ObRb receptor in neurons and glial cells.
Based on these observations and to gain further insight into the
mechanism of action of leptin, we evaluated the inflammatory
response, a key component of SCI pathogenesis and secondary cell
death [34]. Strikingly, leptin treatment induced a significant
decrease in the volume occupied by Iba1
+ microglia/macrophages
and a significant increase in mRNA levels of PPARa, a key
modulator of inflammation, by inhibiting signaling via NF-kb [35].
Accordingly, leptin decreased the expression of NF-kb and IRF-1
mRNA and the downstream inflammatory genes, iNOS and Cox-
2, at both early and chronic stages of SCI. Leptin also promoted a
considerable increase in IL-6 but decreased IL-1b mRNA
expression beginning at 7 d post-SCI. Together, our results point
to a prominent inflammatory modulation by leptin that could be
responsible for at least part of the leptin-induced expression of pro-
survival genes.
Figure 5. The effect of leptin administration on motor function
recovery in the open-field test. (A) Recovery of motor functioning
was determined using the Basso-Beattie-Bresnahan (BBB) locomotor
scale. Leptin administration enhanced the recovery of motor functions
at 1, 3, 7 and 28 d after SCI when compared with vehicle-treated
controls. (B) The BBB sub-scores (7–28 d post-SCI) were significantly
higher following leptin administration. In all cases, the values represent
the mean 6 SEM; *p,0.05 versus the vehicle control group.
doi:10.1371/journal.pone.0035594.g005
Figure 4. Leptin prevents the induction of the expression of inflammatory genes. Leptin administration significantly increased PPARa
mRNA expression (A), while no differences in PPARc mRNA expression (B) were detected 24 h post-SCI when compared with the vehicle-treated
controls. Moreover, leptin treatment significantly decreased IRF-1 (C) and NF-kb (D) mRNA expression 24 h post-SCI. The gene expression of IL-1b and
iNOS (E) was significantly decreased 7 d post-SCI and remained down-regulated until 28 d post-SCI. However, IL-6 mRNA expression was up-
regulated after leptin administration and no effect on TNF-a mRNA levels (E) was detected when compared with vehicle-treated controls. (F) Leptin
administration induced a significant decrease in Cox-2 and p-STAT3 (Tyr 705) protein levels when compared with vehicle-treated controls. Cox-2 and
p-STAT3 (Tyr 705) proteins were significantly decreased 24 h post-SCI and remained down-regulated until 28 d post-SCI. The white lines in the
western blot analysis (F) represent the lanes that were run on the same gel but were non-contiguous. The data in (F) are presented as a percentage of
the corresponding value in the vehicle-treated control group 24 h post-SCI. The values in A–F represent the mean 6 SEM; *p,0.05 versus the vehicle
control group.
doi:10.1371/journal.pone.0035594.g004
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scar, a key obstacle that acts as a barrier to regenerating axons and
impairs functional recovery after SCI [36]. Our results show that
ObRb is expressed in astrocytes after SCI and that leptin
treatment promotes a significant reduction in microglia/macro-
phage reactivity with a concomitant decrease in NF-kb mRNA
expression, a well-known transcriptional regulator of molecules
responsible for proteoglycan synthesis [37]. Although leptin does
not seem to have any effect on GFAP immunoreactivity, it does
increase decorin mRNA levels [38,39]. Decorin is a small
desmatan/chondroitin sulfate proteoglycan that acts as a natural
inhibitor of scar formation by reducing the expression of neurocan
and phosphacan proteoglycans [38–40]. Moreover, leptin also
induced the up-regulation of IL-6, p-CREB and Bcl-2 from 7 d
post-SCI. These proteins have been linked to synaptic plasticity,
dendritic growth, neuritogenesis and axon regeneration [41,42].
Indeed, several studies have described the modulation of axonal
growth and synaptic plasticity by leptin [43–45].
Overall, as a result of its pro-survival and immunomodulatory
action, the remarkable finding of this work is that a single acute
Figure 6. The effect of leptin administration on motor function recovery in the CatWalk system. Gait assessment was performed using
the CatWalkH gait analysis system (version 7.1; Noldus) at 28 d post-SCI in 5 uninterrupted and consistent pace trials per animal. Leptin administration
decreased the base of support (BOS) of both of the fore (A) and hind (B) paws when compared with vehicle-treated controls. The right/left print
position (C and D) and the front/hind paw angle (E and F) in leptin-treated animals were significantly lower than in vehicle-treated controls. (G)
Examples of the step sequence pattern analysis in representative vehicle-treated and leptin-treated animals. The values in A–F represent the mean 6
SEM; **p,0.0001 versus the basal values in pre-lesioned conditions; *p,0.001 versus the vehicle control group.
doi:10.1371/journal.pone.0035594.g006
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and sensory function after SCI. Importantly, in contrast to earlier
reports on a sciatic chronic constriction injury model [46,47],
leptin administration prevented the development of thermal
hyperalgesia and mechanical allodynia in our model of SCI. In
this regard, these studies showed that the effect of leptin on spinal
NMDA currents was mediated through leptin receptors, concrete-
ly by activating the JAK2/STAT3 signaling pathway. In line,
leptin induced the up-regulation of the expression of NR1 and p-
STAT3, which was also mediated through NMDAR. Although
therapeutic approaches to prevent chronic pain after injury are
limited, at the molecular level, the selective inhibition of Cox-2,
iNOS and p-STAT3 activity can attenuate neuropathic pain
[48,49]. Accordingly, we observed a decrease in Cox-2 protein
levels and iNOS mRNA expression with a concomitant attenu-
ation of p-STAT3 in leptin-treated animals. Given that contusion
injury is a valid model for the analysis of neuropathic pain [50],
the present findings provide new evidence that leptin has beneficial
effects in pain management after moderate contusive SCI. In this
context, it should be noticed that the different experimental
models might account for the divergence observed in the effects of
Figure 7. Electrophysiological assessment and neuropathic pain. Electrophysiological tests were carried out at 28 d post-SCI to analyse the
motor evoked potentials (MEPs). Leptin administration significantly increased the average maximum amplitude (A) and rectified area under the curve
(B) when compared with vehicle-treated controls. (C and D) At 28 d post-SCI, vehicle-treated controls exhibited a significant decrease in paw
withdrawal latency when compared with the basal values determined in pre-lesioned conditions, indicative of thermal hyperalgesia. Leptin
administration had no effect on the thermal delay when compared with the basal values determined in pre-lesioned conditions, indicating an
attenuation of neuropathic pain. In terms of nociception, we observed similar mean latencies of heat-induced paw withdrawal in leptin-treated
animals when compared with pre-lesioned conditions (8.0160.36 seconds), while a significant decrease in latency was observed in the vehicle
control group (6.8460.25 seconds). Similarly, mechanical stimulation with Von-Frey filaments required a significantly lower mean threshold force to
induce hind paw retraction in the vehicle control group (1862.1 grams) following SCI when compared with the basal values determined in pre-
lesioned conditions (2561.67 grams); however, there were no such differences in leptin-treated animals (D). The values in A–D represent the mean 6
SEM. A and B; *p,0.0025 versus the vehicle-treated controls. C and D; **p,0.05 versus the basal values in pre-lesioned conditions; *p,0.05 versus
the vehicle-treated controls.
doi:10.1371/journal.pone.0035594.g007
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this issue.
In conclusion, this study shows that acute leptin administration
enhances the expression of neuroprotective genes, reduces
inflammation and significantly improves sensory and motor
functional outcomes after SCI. Thus, our observations suggest
that leptin might be a promising therapeutic agent to treat CNS
injury given its clinical use in humans [51,52], the ease with which
it can be delivered systemically and the well-known therapeutic
doses [53–55] and its ability to cross the blood brain barrier [56].
Materials and Methods
Experimental design and spinal cord injury
Animals were distributed into two experimental blocks. In the
first experimental block, the expression of endogenous leptin and
ObRb genes was studied at different times after SCI by RT-qPCR
of total mRNA extracted from 21 animals (7 groups: non-lesioned
group (NL), 6 and 24 hours (h) and 3, 7 and 14 days (d) after SCI;
n=3 per group). In the second experimental block,62 animals were
used to evaluate the effects of an acute IP administration of leptin
after SCI in two independent experiments (see Tables S1 and S2).
Figure 8. Leptin administration increases the preservation of caudal white matter. Leptin administration significantly increased the
preservation of white matter when compared with vehicle treated controls, specifically in areas corresponding to caudal levels adjacent to the lesion
epicentre. The values represent the mean 6 SEM; *p,0.05 versus the vehicle-treated controls.
doi:10.1371/journal.pone.0035594.g008
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(300–350 g) in accordance with institutional guidelines for the care
and use of experimental animals (Permit numbers 51/2009 and
45/2008). A moderate spinal cord contusion was created using an
Infinite Horizon Impactor (Precision Systems and Instrumentation
LLC), as previously described [57].
Drug administration
Recombinant rat leptin (Sigma) dissolved in 15 mM Tris HCL
(pH 8.0) or the vehicle alone (15 mM Tris HCL pH 8.0), was
injected 5 min after SCI. These treatments were delivered
stereotaxically (David Kopf Instruments) at the dorsal midline to
a depth of 0.5 mm. They were administered in 3 separate
injections (2 ml/4 mg/each): 1 to the wound epicentre, 1 mm
rostral to the injury epicentre and 1 mm caudal to the injury
Figure 9. Leptin administration decreases microglial/macrophage activation but has no effect on astroglial reactivity. Leptin
administration significantly diminished the presence of Iba1
+ microglia/macrophages when compared with vehicle treated controls, as measured by
the total volume occupied by Iba1
+ microglia/macrophages (A) and the area occupied at multiple rostro-caudal levels (B). No differences between
groups were observed in the total volume occupied by GFAP
+ astrocytes (C) or the area occupied at each rostro-caudal level (D). The values represent
the mean 6 SEM; *p,0.05 versus the vehicle-treated control group. Scale bars=50 mm.
doi:10.1371/journal.pone.0035594.g009
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needle (135 Outer and 55 Inner micrometre diameters) attached
to a 10 ml syringe (World Precision Instruments) and a
microinjector (KD Scientific).
Evaluation of sensory-motor recovery
Animals were tested in multiple sensory-motor tasks, including
the BBB open field test, the CatWalkH gait analysis system, the
Hargreaves heat and von Frey mechanical elicited withdrawal
response.
1. Locomotor function assessment. In the open-field test,
the 21-point BBB scale [29] was used to measure movement,
weight support and coordination following recovery after SCI
[29]. One week prior to SCI, all animals were trained and
evaluated to exclude animals with any intrinsic motor dysfunction.
After injury, the BBB open field test was performed by 2
examiners blinded to the experimental procedures to assess the
spontaneous locomotor recovery on days 1, 3, 7, 14, 21 and 28.
In the first experimental block, 21 animals were used for total
mRNA extraction at specific times post-SCI. The open-field test
was carried out to establish a homogeneous group, and only
animals with a BBB score of 0–3 one day after surgery and with
similar functional progress were included in the study.
In the second experimental block, 62 animals were used to
evaluate the effects of IP leptin administration. The BBB scale and
the BBB sub-score were used to analyse the differences in
functional recovery due to leptin administration. In this regard,
the BBB scores were further analysed by calculating sub-scores
[58–60], which allows for characterisation of the individual aspects
of locomotion, alone or in combination.
To assess the effects of leptin treatment on locomotor gait
dynamics, we used the CatWalkH gait analysis system (version 7.1;
Noldus) as previously described [61],[62]. Individual footprints
were visualised by slightly dampening the rats’ feet with a 50%
glycerol solution. Animals subjected to SCI and IP administration
of vehicle or leptin were trained for 5 min daily in the week
preceding functional assessment. For each animal, a minimum of 5
Figure 10. The effect of leptin treatment on PPARs, NF-kb and decorin in the chronic phase of SCI. The expression of PPARa (A), PPARb/d
(B), PPARc (C), NF-kb (D) and decorin (E) were quantified by RT-qPCR 28 d post-SCI. As shown, a significant up-regulation of PPARa and PPARb/d
mRNA expression was observed in leptin-treated animals. No differences were detected in the mRNA expression of PPARc when compared with
vehicle-treated controls. Moreover, a significant decrease in NF-kb mRNA expression and an increase in decorin mRNA expression were observed in
leptin-treated animals. The values in A–E represent the mean 6 SEM; *p,0.05 versus the vehicle-treated controls.
doi:10.1371/journal.pone.0035594.g010
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(to obtain pre-lesioned basal reference values) or at the completion
of the study. To simplify the study and allow for a quick and easy
interpretation of the functional outcome, we chose 3 well-
established parameters for foot prints analysis [63]: the BOS,
print position, and angle parameters.
2. Evaluation of sensory recovery. Sensory function was
assessed by analysing thermal hyperalgesia and mechanical
allodynia at the end of the study (28 d post-SCI) in animals
subjected to SCI and IP administration.
-Thermal hyperalgesia: the thermal sensitivity of the hind paw
plantar surface was tested by means of a Hargreaves Plantar Test
Apparatus (Ugo Basile), as previously described [64]. Paw
withdrawal latency in response to a heating stimulus was
performed in 3 consecutive trials on each animal, with a cutoff
latency of 20 s to avoid tissue damage, at both 3 days before injury
to establish pre-lesioned basal reference values and 28 d after
injury. A decrease in withdrawal latency of .3 s was considered as
neuropathic pain.
-Mechanical allodynia: at the same time points when thermal
hyperalgesia was assessed, the tactile sensory response to
mechanical stimuli was evaluated by stimulation of the hind paw
plantar surface with a calibrated set of von Frey filaments
(Stoelting Co. Wood Dale, IL). Briefly, animals were placed in
individual Plexiglas chambers with a plastic mesh floor for at least
30 min. Filaments were then applied to the bending point for 6 s,
and brisk paw withdrawal was considered as a positive response.
The response threshold was determined as the lowest force that
provoked a minimum of 50% positive retractions from a total of 20
stimulations per paw [65,66].
The animals from the different experimental groups were
randomly tested by two observers blinded to the treatments.
Electrophysiological assessment
An electrophysiological assessment of spinal cord function was
performed by brain stimulation and hind limb MEPs recording in
both limbs of each animal at the end of the study (28 d post-SCI),
as previously described with minor modifications [67]. Briefly,
animals were anesthetised with pentobarbital (40 mg/kg i.p.) and
placed in a prone position on a homoeothermic blanket to
maintain their body temperature at 37uC. First, the lumbar
circuitry state was assessed by means of electrical stimulation of the
sciatic nerve with single electrical pulses of 0.1 milliseconds (ms)
duration and supra-maximal intensity delivered by monopolar
needles percutaneously inserted at the sciatic notch. The
compound muscle potential (cMAP) of the gastrocnemius and
tibialis anterior muscles was recorded by means of needle
electrodes, with the active electrode on the belly of the muscle
and the reference at the second toe with Signal software
(Cambridge Electronic Design Ltd.). The latency and amplitude
of the average direct muscle response (M-wave) resulting from 5
consecutive recordings was analysed using the same software.
Without moving the recording electrodes, stimulation electrodes
were placed subcutaneously over the skull, with the anode over the
motor cortex and the cathode on the hard palate, to deliver pulses
of 2 ms duration and supramaximal intensity. A total of 20–25
independent recordings of MEPs were acquired, amplified and
filtered (10–1000 Hz) from the gastrocnemius and tibialis anterior
muscles of both limbs of each animal. The resulting average
recordings were analysed for latency, amplitude and rectified area
(Modulus) of the negative peak. Values are represented as the
group mean and SEM of the average values resulting from the
gastrocnemius and tibialis anterior muscles of both limbs of each
animal. To ensure recording confidence, 2 additional animals
were used in a preliminary experiment to corroborate a total lack
of elicited MEPs after a whole spinal cord transection (data not
shown).
mRNA isolation and RT-qPCR
Multiple mRNA transcripts were quantified by RT-qPCR
including leptin, ObRb, PPARs, IL-1b, IL-6, TNF-a, IRF-1,
NF-kb, catalase, GPx, iNOS and decorin.
Total RNA was isolated from a 1-cm-long spinal cord fragment
that contained the wound epicentre using the RNeasy Lipid Mini
Kit (Qiagen). Reverse transcription from 3 mg of DNase-treated
RNA and RT-qPCR was carried out using specific primers
(Table 1), as previously described [57].
Western blot
Denatured protein samples (100 mg) were resolved on 10%
SDS-PAGE gels, transferred to PVDF membranes and incubated
with a primary antibody raised against p-CREB (1:500; Santa
Cruz Technology), Bcl-xL (1:500; Abcam), Bcl-2 (1:250; Abcam),
p-STAT3 Tyr705 (1:1000; Cell Signaling Technology) or Cox-2
(1:500; BD Laboratories). A corresponding anti-rabbit or anti-
mouse horseradish peroxidase (HRP)-conjugated secondary anti-
body (1:7000; Amersham) was used as previously described [57].
Caspase-3 activity
Caspase-3 activity was measured using the Caspase-Glo Assay
System (Promega) according to the manufacturer’s instructions.
Briefly, 50 ml of the Caspase-Glo buffer was added to 100 mgo f
total protein in a 96-well plate. After incubating at RT for 60 min,
the luminescence was measured on an Infinite M200 microplate
reader (Tecan). Standard curves were used to determine the
linearity of the responses.
Histology and IHC
Animals were anesthetised with pentobarbital and perfused
intracardially with 150 ml of heparinised saline solution followed
by 1 ml/g of 4% paraformaldehyde. Spinal cord fragments 2 cm
in length (1 cm rostral and 1 cm caudal to the wound epicentre)
were immediately dissected, post-fixed for 4 h in the same fixative
solution, and then cryoprotected by immersion in 30% sucrose for
48 h and embedded in Neg-50 medium (Richard-Allan Scientific)
and stored at 220uC. Parallel serial cryosections (30 mm thick)
were then cut, mounted on slides and stored at 220uC.
Cellular ObRb expression was evaluated in different cell types
in a set of parallel sections from uninjured (n=5) and from vehicle
and leptin-treated animals sacrificed at 24 h post-injury (see table
S1) by dual IHC against adenomatous polyposis coli (APC;
oligodendrocytes), NeuN (neurons), GFAP (astrocytes) or OX-42
(microglia/macrophages). Briefly, sections were treated for 1 h at
RT with a Blocking Buffer (BB) containing 10% FBS, 0.3% BSA
and 0.3% Triton X-100 in (pH 7.4) TBS, followed by incubation
overnight at 4uC plus 1 h at RT with a rabbit anti-ObRb (1:100;
Abcam) primary antibody in BB. After washing, the sections were
incubated for 1 h at RT with an Alexa 488-linked anti-rabbit
secondary antibody (1:1000; Invitrogen) in BB with 10% rat serum
instead of FBS. The sections were then washed again and blocked
with BB for 1 h at RT before immunostaining as above but with
an Alexa 594-linked anti-mouse antibody and one of the following
primary mouse antibodies: APC (1:100; Calbiochem), NeuN
(1:250; Chemicon), GFAP (1:1000; Sigma) or OX-42 (1:500;
Wako). Finally, the slides were coverslipped in ‘‘Immumount’’
(Thermo Scientific) and confocal images were collected at RT on a
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6361.40 NA oil objectives and LAS-AF software (Leica).
To evaluate astroglial and microglia/macrophage reactivity,
GFAP and Iba1 IHC were performed on a set of parallel sections
from each animal euthanised at the end of the study. Briefly,
sections were treated for 10 min with 2% H2O2 in a 70% methanol
solution at RT, immersed for 1 h at RT with BB and incubated
overnight at 4uC plus 1 h at RT with rabbit anti-GFAP (1:1000;
Dako) or rabbit anti-Iba1 (1:1000; Wako). After washing, the
sections were incubated with a biotinylated anti-rabbit secondary
antibody (1:500; Vector) in BB and then with HRP-linked
streptavidin (1:500; Perkin Elmer) and visualised using the Nova
Red Kit (Vector), according to the manufacturer’s instructions. The
sections were dehydrated in graded ethanol and coverslipped in
DPX (Panreac). Images were acquired on a BX61 Motorized
Research Microscope (Olympus) and the immunoreactive volume
and area were quantified with ImageJ software, either in the total
spinal cord volume or at each rostro-caudal spinal cord level
analysed(8sectionsperanimalseparatedby600 mmandcontaining
the wound epicentre). The data corresponding to the total
immunoreactive volume and area per rostro-caudal level are
presented, respectively, as the percentage of total spinal cord
volume and spinal cord area per rostro-caudal level.
In each single IHC experiment, processed sections lacking
primary antibody were used as controls. For dual immunohisto-
chemistry and to identify putative cross reactivity between the
second secondary antibody and the first primary antibody,
processed sections lacking the second primary antibody were used
as controls.
Myelin preservation was assessed by eriochrome cyanine
staining (ECy) in 1 set of parallel sections from each animal at
28 d post-SCI. Briefly, slides were air-dried for 2 h, dehydrated in
acetone for 5 min and stained by immersion in 0.2% eriochrome
cyanine plus 0.4% iron alum for 30 min. Gray matter (gray) and
white (dark blue) matter were differentiated by incubation in 5%
iron alum, followed by 1% Borax and 1.25% potassium
ferricyanide for 15 min each. Finally, sections were rinsed with
tap water, dehydrated with graded ethanol solutions, cleared with
xylol and coverslipped with DPX. Myelin preserved areas were
analysed by densitometry with ImageJ software. The data
corresponding to preserved myelin are presented as the percentage
of the spinal cord area in each rostro-caudal level.
Statistical analysis
All values are expressed as the mean 6 SEM. In the analysis of
locomotion in an open field, groups were compared using two-way
repeated measures ANOVA, followed by a Bonferroni post-hoc
analysis. The nonparametric Mann-Whitney U test was used to
determine differences in the withdrawal latency and threshold
force in the response to heating or von Frey filament stimulation.
Data from the CatWalkH gait analysis, electrophysiological
assessment, IHC, western blot and RT-qPCR were compared
using a one-way ANOVA followed by a Tukey post-hoc and t-tests
for a point-to-point comparison. In all cases, P,0.05 was
considered to be statistically significant. All statistical analyses
were performed using GraphPad Prism (version 4.0).
Supporting Information
Figure S1 The principal categories within the BBB scale
are improved by leptin treatment. (A) Significantly more
rats in the leptin treatment group recovered the ability to step by
7 d post-SCI when compared with vehicle treated rats. (B) There
was a significantly improved toe clearance over time in leptin-
treated rats at 14, 21 and 28 d post-SCI. (C) Paw position
subscores, due to more frequent parallel paw placements,
increased over time in the leptin-treated animals when compared
with the vehicle controls. (D) Finally, the leptin-treated group
displayed more frequent forelimb-hindlimb coordination than the
vehicle-treated rats at 21 and 28 d post-SCI. In all cases, values
represent the mean 6 SEM; *p,0.05 versus the vehicle control
group.
(TIF)
Table S1 The distribution of animals subjected to SCI
and IP leptin/vehicle administration (experiment I).
(DOC)
Table S2 The distribution of animals subjected to SCI
and IP leptin/vehicle administration (experiment II).
(DOC)
Table 1. RT-qPCR primers.
Gene name Forward primer Reverse primer Acc no.
Catalase 59-GTACAGGCCGGCTCTCACA-39 59-ACCCGTGCTTTACAGGTTAGCT-39 NM_012520
Decorin 59-AGCAACCCTGTCCGGTATTG-39 59-CGCCCGAAGACACATCTGA-39 NM_024129
GPx 59-GCTGTGCGCGCTCCAT-39 59-ACCATGTGCCCATCGATGT-39 NM_017165
IL-1b 59-GACCTGTTCTTTGAGGCTGACA-39 59-AGTCAAGGGCTTGGAAGCAA-39 NM_031512
IL-6 59-CCCACCAGGAACGAAAGTCA-39 59-GCGGAGAGAAACTTCATAGCTGTT-39 NM_012589
iNOS 59-TGGTGAAAGCGGTGTTCTTTG-39 59-ACGCGGGAAGCCATGA-39 NM_012611
IRF-1 5-AACTTCCGGTGTGCCATGA-39 59-TCCTGCTCTGGTCCTTCACTTC-39 NM_012591
Leptin 59-CTTCATTCCCGGGCTTCA-39 59-GCCAGGGTCTGGTCCATCTT-39 NM_013076
NF-kb 59-TCGTGAGGGATCTGCTAGAAGTG-39 59-GTTGCCTCCAGATCCACAAAC-39 NM_001107095
PPARa 5-AGGCCTCAGGATACCACTATGG-39 5-CCGAAAGAAGCCCTTGCA-39 NM_013196
PPARb/d 5-GCTCACTGACAGATGAGGACAAA-39 5-CTGGGTCTGAGCGCAGATG-39 NM_013141
PPARc 5-CCCACCAACTTCGGAATCAG-39 5-GGAATGGGAGTGGTCATCCA-39 NM_013124
TNF-a 59-CCCAGAAAAGCAAGCAACCA-39 59-GCCTCGGGCCAGTGTATG-39 NM_012675
The primers used for RT-qPCR analysis of the genes assessed in this study, including the gene symbol, primer sequences (forward and reverse sequences, respectively)
and the Genbank accession number.
doi:10.1371/journal.pone.0035594.t001
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